Disappointed to hear that CARGO’s CD22 #CAR-T results underperformed.
Many other new and promising immunotherapies being developed for aggressive B-cell lymphoma! investors.cargo-tx.com/news-release...
investors.cargo-tx.com
Chief of Blood Disorders, Rutgers Cancer Institute. Lymphoma doc, dad of 3, practicing and preaching kindness in both medicine and life.